Genomic Medicine: Genetic Variation and Its Impact on the Future of Health Care

Overview

Journal Philos Trans R Soc Lond B Biol Sci

Specialty Biology

Date 2005 Aug 13

PMID 16096102

Citations 17

Authors

Huntington F Willard

Misha Angrist

Geoffrey S Ginsburg

Affiliations

Soon will be listed here.

Abstract

Advances in genome technology and other fruits of the Human Genome Project are playing a growing role in the delivery of health care. With the development of new technologies and opportunities for large-scale analysis of the genome, transcriptome, proteome and metabolome, the genome sciences are poised to have a profound impact on clinical medicine. Cancer prognostics will be among the first major test cases for a genomic medicine paradigm, given that all cancer is caused by genomic instability, and microarrays allow assessment of patients' entire expressed genomes. Analysis of breast cancer patients' expression patterns can already be highly correlated with recurrence risks. By integrating clinical data with gene expression profiles, imaging, metabolomic profiles and proteomic data, the prospect for developing truly individualized care becomes ever more real. Notwithstanding these promises, daunting challenges remain for genomic medicine. Success will require planning robust prospective trials, analysing health care economic and outcome data, assuaging insurance and privacy concerns, developing health delivery models that are commercially viable and scaling up to meet the needs of the whole population.

Citing Articles

Is everyone a mix of straight and gay? A social pressure theory of sexual orientation, with supporting data from a large global sample.

Epstein R, Wang H, Zankich V Front Psychol. 2023; 14:1187377.

PMID: 37496790 PMC: 10367109. DOI: 10.3389/fpsyg.2023.1187377.

FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine.

Luh F, Yen Y NPJ Genom Med. 2018; 3:28.

PMID: 30302274 PMC: 6170456. DOI: 10.1038/s41525-018-0067-2.

De novo vs. inherited copy number variations in multiple sclerosis susceptibility.

Tizaoui K Cell Mol Immunol. 2018; 15(9):812-814.

PMID: 29429997 PMC: 6203723. DOI: 10.1038/cmi.2017.166.

Next-Generation Sequencing: The Translational Medicine Approach from "Bench to Bedside to Population".

Beigh M Medicines (Basel). 2017; 3(2).

PMID: 28930123 PMC: 5456221. DOI: 10.3390/medicines3020014.

Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond.

Schork N, Nazor K Adv Genet. 2017; 97:81-113.

PMID: 28838357 PMC: 6383766. DOI: 10.1016/bs.adgen.2017.06.001.

References

Van Scoik K, Johnson C, Porter W . The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev. 1985; 16(1-2):157-74. DOI: 10.3109/03602538508991433. View

Lazarou J, Pomeranz B, Corey P . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15):1200-5. DOI: 10.1001/jama.279.15.1200. View

Pritchard S, Powrie R, Sludden J, Collier D, Li T, McLeod H . The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999; 9(1):37-42. DOI: 10.1097/00008571-199902000-00006. View

Bundorf M, Singer S, Wagner T, Baker L . Consumers' use of the Internet for health insurance. Am J Manag Care. 2004; 10(9):609-16. View

Cara C, Pena A, Sans M, Rodrigo L, Guerrero-Esteo M, Hinojosa J . Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 2004; 10(11):RA247-54. View

Wulfkuhle J, Espina V, Liotta L, Petricoin E . Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer. 2004; 40(17):2623-32. DOI: 10.1016/j.ejca.2004.05.020. View

Kenna G, McGeary J, Swift R . Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health Syst Pharm. 2004; 61(21):2272-9. DOI: 10.1093/ajhp/61.21.2272. View

Burns M, He W, Wu C, Cheng L . Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat. 2004; 3(6):591-8. DOI: 10.1177/153303460400300609. View

Angell M . Excess in the pharmaceutical industry. CMAJ. 2004; 171(12):1451-3. PMC: 534578. DOI: 10.1503/cmaj.1041594. View

10.

Wheeler D, Barrett T, Benson D, Bryant S, Canese K, Church D . Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2004; 33(Database issue):D39-45. PMC: 540016. DOI: 10.1093/nar/gki062. View

11.

Bentley D . Genomes for medicine. Nature. 2004; 429(6990):440-5. DOI: 10.1038/nature02622. View

12.

Thrall J . Personalized medicine. Radiology. 2004; 231(3):613-6. DOI: 10.1148/radiol.2313040323. View

13.

Shastry B . SNP alleles in human disease and evolution. J Hum Genet. 2002; 47(11):561-6. DOI: 10.1007/s100380200086. View

14.

Chung C, Bernard P, Perou C . Molecular portraits and the family tree of cancer. Nat Genet. 2002; 32 Suppl:533-40. DOI: 10.1038/ng1038. View

15.

Garber K . Debate rages over proteomic patterns. J Natl Cancer Inst. 2004; 96(11):816-8. DOI: 10.1093/jnci/96.11.816. View

16.

Pittman J, Huang E, Dressman H, Horng C, Cheng S, Tsou M . Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A. 2004; 101(22):8431-6. PMC: 420411. DOI: 10.1073/pnas.0401736101. View

17.

Abbate A, Biondi-Zoccai G, Brugaletta S, Liuzzo G, Biasucci L . C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med. 2004; 3(4):375-84. DOI: 10.1055/s-2004-815695. View

18.

Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9. PMC: 443443. DOI: 10.1136/bmj.329.7456.15. View

19.

Seibert V, Wiesner A, Buschmann T, Meuer J . Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract. 2004; 200(2):83-94. DOI: 10.1016/j.prp.2004.01.010. View

20.

Bukowska A, Lendeckel U, Kahne T, Goette A . Proteomics in myocardial diseases. Pathol Res Pract. 2004; 200(2):135-45. DOI: 10.1016/j.prp.2004.02.004. View